# EDGAR Filing Document

**Accession Number:** 0001833141
**File Stem:** 0001833141-25-000031
**Filing Date:** 2025-11
**Character Count:** 4767
**Document Hash:** 5206924d67fae07718df019622dc256e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001833141-25-000031.hdr.sgml**: 20251103

**ACCESSION NUMBER**: 0001833141-25-000031

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20251103

**FILED AS OF DATE**: 20251103

**DATE AS OF CHANGE**: 20251103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CYBIN INC.
- **CENTRAL INDEX KEY:** 0001833141
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40673
- **FILM NUMBER:** 251443541

**BUSINESS ADDRESS:**
- **STREET 1:** 100 KING STREET WEST
- **STREET 2:** SUITE 5600
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5X 1C9
- **BUSINESS PHONE:** (908) 764-8385

**MAIL ADDRESS:**
- **STREET 1:** 100 KING STREET WEST
- **STREET 2:** SUITE 5600
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5X 1C9

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**<br>**Form 6-K**<br>**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934**<br>

For the month of November, 2025.

Commission File Number: **001-40673**

****<br>**<u>Cybin Inc.</u>**<br>(Exact Name of Registrant as Specified in Charter)<br>**100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9** 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F □ Form 40-F ⊠

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br>

---

| | | | |
|:---|:---|:---|:---|
| | | **CYBIN INC.** | **CYBIN INC.** |
| | | (Registrant) | (Registrant) |
| Date: | November 3, 2025 | By: | */s/ Greg Cavers&nbsp;&nbsp;&nbsp;&nbsp;*  |
|  |  | Name: | Greg Cavers |
|  |  | Title: | Chief Financial Officer |

---

------

**<u>EXHIBIT INDEX</u>**

99.1 <u>[News Release dated November 3, 2025](a11-03x2025milkenfutureofh.htm)</u>

## Exhibit 99.1

![image_0.jpg](image_0.jpg)

**Cybin to Participate at the 2025 Milken Institute Future of Health Summit**

*- Chief Medical Officer Amir Inamdar to participate in a panel on November 5, 2025 -*

**TORONTO, CANADA** – November 3, 2025 – <u>Cybin Inc.</u> (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that Amir Inamdar, Cybin's Chief Medical Officer, will participate in a panel at the 2025 Milken Institute Future of Health Summit, taking place November 4-6, 2025, in Washington, D.C. The panel details are as follows:

**Panel title:** <u>Reimagining Mental Health: Innovation at the Intersection of Care and Technology</u>

**Date:** Wednesday, November 5, 2025

**Time:** 2:00 – 3:00 PM ET

To access the live panel discussion, please <u>click here</u>. The archived webcast will also be available on the Company's investor relations website on the <u>Events & Presentations</u> page.

**About Cybin**

Cybin is a breakthrough Phase 3 clinical-stage neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

------

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, and Ireland.

**Investor Contact:** 

Josh Barer

astr partners

Managing Director

(908) 578-6478

<u>josh.barer@astrpartners.com</u>

<br>George Tziras<br>Chief Business Officer<br>Cybin Inc.<br>1-866-292-4601<br><u>irteam@cybin.com</u> – or – <u>media@cybin.com</u>

<br>